Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Clinical Laboratories, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Scand J Clin Lab Invest. 2020 Oct;80(6):441-447. doi: 10.1080/00365513.2020.1768587. Epub 2020 May 23.
The Coronavirus Disease (COVID-19) pandemic first broke out in December 2019 in Wuhan, China, and has now spread worldwide. Laboratory findings have been only partially described in some observational studies. To date, more comprehensive systematic reviews of laboratory findings on COVID-19 are missing. We performed a systematic review with a meta-analysis to assess laboratory findings in patients with COVID-19. Observational studies from three databases were selected. We calculated pooled proportions and 95% confidence interval (95% CI) using the random-effects model meta-analysis. A total of 1106 articles were identified from PubMed, Web of Science, CNKI (China), and other sources. After screening, 28 and 7 studies were selected for a systematic review and a meta-analysis, respectively. Of the 4,663 patients included, the most prevalent laboratory finding was increased C-reactive protein (CRP; 73.6%, 95% CI 65.0-81.3%), followed by decreased albumin (62.9%, 95% CI 28.3-91.2%), increased erythrocyte sedimentation rate (61.2%, 95% CI 41.3-81.0%), decreased eosinophils (58.4%, 95% CI 46.5-69.8%), increased interleukin-6 (53.1%, 95% CI 36.0-70.0%), lymphopenia (47.9%, 95% CI 41.6-54.9%), and increased lactate dehydrogenase (LDH; 46.2%, 95% CI 37.9-54.7%). A meta-analysis of seven studies with 1905 patients showed that increased CRP (OR 3.0, 95% CI: 2.1-4.4), lymphopenia (OR 4.5, 95% CI: 3.3-6.0), and increased LDH (OR 6.7, 95% CI: 2.4-18.9) were significantly associated with severity. These results demonstrated that more attention is warranted when interpreting laboratory findings in patients with COVID-19. Patients with elevated CRP levels, lymphopenia, or elevated LDH require proper management and, if necessary, transfer to the intensive care unit.
新型冠状病毒病(COVID-19)疫情于 2019 年 12 月在中国武汉首次爆发,并已在全球范围内传播。一些观察性研究仅部分描述了实验室发现。迄今为止,还缺少对 COVID-19 实验室发现的更全面系统的综述。我们进行了一项系统评价和荟萃分析,以评估 COVID-19 患者的实验室发现。从三个数据库中选择了观察性研究。我们使用随机效应模型荟萃分析计算合并比例和 95%置信区间(95%CI)。从 PubMed、Web of Science、CNKI(中国)和其他来源共确定了 1106 篇文章。经过筛选,分别有 28 篇和 7 篇研究被纳入系统评价和荟萃分析。在纳入的 4663 名患者中,最常见的实验室发现是 C 反应蛋白(CRP)升高(73.6%,95%CI 65.0-81.3%),其次是白蛋白降低(62.9%,95%CI 28.3-91.2%)、红细胞沉降率升高(61.2%,95%CI 41.3-81.0%)、嗜酸性粒细胞减少(58.4%,95%CI 46.5-69.8%)、白细胞介素-6(53.1%,95%CI 36.0-70.0%)、淋巴细胞减少(47.9%,95%CI 41.6-54.9%)和乳酸脱氢酶(LDH)升高(46.2%,95%CI 37.9-54.7%)。荟萃分析了 7 项研究,共纳入 1905 例患者,结果显示 CRP 升高(OR 3.0,95%CI:2.1-4.4)、淋巴细胞减少(OR 4.5,95%CI:3.3-6.0)和 LDH 升高(OR 6.7,95%CI:2.4-18.9)与疾病严重程度显著相关。这些结果表明,在解释 COVID-19 患者的实验室发现时需要更加注意。CRP 水平升高、淋巴细胞减少或 LDH 升高的患者需要进行适当的管理,如有必要,应转至重症监护病房。